RNA interference mediated inhibition of platelet-derived...

Details RNA interference mediated inhibition of platelet-derived... RNA interference mediated inhibition of platelet-derived...

2011-03-01

2011-03-01

McGarry, Sean (Department: 1635)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

Reexamination Certificate

active

07897755

ABSTRACT:
This invention relates to compounds, compositions, and methods useful for modulating platelet-derived endothelial cell growth factor and/or receptor (ECGF1 and/or ECGF1r) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of ECGF1 and/or ECGF1r gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of ECGF1 and/or ECGF1r genes.

REFERENCES:
patent: 5814620 (1998-09-01), Robinson et al.
patent: 5998203 (1999-12-01), Matulic-Adamic et al.
patent: 5998206 (1999-12-01), Cowsert
patent: 7678897 (2010-03-01), McSwiggen et al.
patent: 2003/0083294 (2003-05-01), Sullenger et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2005/0020521 (2005-01-01), Rana
patent: 2005/0080246 (2005-04-01), Allerson et al.
patent: 2359180 (2000-03-01), None
patent: WO-90/14090 (1990-11-01), None
patent: WO-94/01550 (1994-01-01), None
patent: WO-99/32619 (1999-07-01), None
patent: WO-99/49029 (1999-09-01), None
patent: WO-00/44895 (2000-08-01), None
patent: WO-00/44914 (2000-08-01), None
patent: WO-01/36646 (2001-05-01), None
patent: WO-01/96584 (2001-12-01), None
patent: WO-01/96584 (2001-12-01), None
patent: WO-02/22636 (2002-03-01), None
patent: WO-02/44321 (2002-06-01), None
patent: WO-02/44321 (2002-06-01), None
patent: WO-03/064626 (2003-08-01), None
patent: WO-03/064626 (2003-08-01), None
Parrish et al. (Molecular Cell, 2000, vol. 6: 1077-1087).
Pieken et al. (Science, 1991, vol. 253: pp. 314-317).
Caplen (Expert Opin Biol Ther, Jul. 2003, 3(4), pp. 575-586).
GenBank Accession No. NM—001953, downloaded from http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=4557668, downloaded Jul. 8, 2005.
Anderson et al. “Bispecific Short Hairpin siRNA Constructs Targeted to CD4, CXCR4, and CCR5 Confer HIV-1 Resistance,”Oligonucleotides13(5):303-312 (2003).
Bertrand et al. “Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo,” Biochem. Biophys. Res. Comm. 296:1000-1004 (2002).
Braasch et al. “RNA Interference in Mammalian Cells by Chemically-Modified RNA,” Biochem. 42:7967-7975 (2003).
Britz-Cunningham et al. “Molecular Targeting with Radionuclides: State of the Science,” J. Nucl. Med. 33:1945-1961 (2003).
Elbashir et al. “Analysis of Gene Function in Somatic Mammalian Cells Using Small Interfering RNAs,”Methods26(2):199-213 (2002).
Elbashir et al. “Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells,”Nature411(6836):494-498 (2001).
Elbashir et al. “Functional Anatomy of siRNAs for Mediating Efficient RNAi inDrosophila melanogasterEmbryo Lysate,”EMBO J. 20(23):6877-6888 (2001).
Elbashir et al. “RNA Interference is Mediated by 21- and 22-Nucleotide RNAs,”Genes Dev. 15(2):188-200 (2001).
Fire et al. “Potent and Specific Genetic Interference by Double-Stranded RNA inCaenorhabditis elegans,” Nature391:806-811 (1998).
Futami et al. “Induction of Apoptosis in HeLa Cells with siRNA Expression Vector Targeted Against Bcl-2,”Nucleic Acids Research Supplement2:251-252 (2002).
International Search Report mailed on Mar. 31, 2005 for PCT/US04/16390, 2 pages.
International Search Report mailed on Oct. 17, 2003 for PCT/US03/05028, 2 pages.
International Search Report mailed on Oct. 17, 2003 for PCT/US03/05346, 1 page.
Kurreck et al. “Design of antisense oligonucleotides stabilized by locked nucleic acids,” Nucl. Acids Res. 30:1911-1918 (2002).
Leirdal et al. “Gene Silencing in Mammalian Cells by Preformed Small RNA Duplexes,”Biochemical and Biophysical Research Communications295:744-748 (2002).
Lin et al. “A Novel mRNA-cDNA Interference Phenomenon for Silencing Bcl-2 Expression in Human LNCaP Cells,”Biochemical and Biophysical Research Communications281:639-644 (2001).
Mader et al. “Transcription and Activity of 5-Fluorouracil Converting Enzymes in Fluoropyrimidine Resistance in Colon Cancer in Vitro,” Biochem. Pharama. 54:1233-1242 (1997).
Olie et al. “Analysis of Ribosyl-Modified, Mixed Backbone Analogs of a bcl-2/bcl-xL Antisense Oligonucleotide,” Biochim. Biophys. Acta 1576:101-109 (2002).
Scanlon “Anti-Genes: siRNA, Ribozymes and Antisense,” Curr. Pharma. Biotech. 5:415-420 (2004).
Tuschl et al. “Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy,”Molecular Interventions295(3):158-167 (2002).
Tuschl et al. “Targeted mRNA Degradation by Double-Stranded RNA In Vitro,”Genes and Development13(24):3191-3197 (1999).
Office Action mailed on Feb. 4, 2008 for U.S. Appl. No. 10/444,853, 37 pages.
Office Action mailed on Jul. 1, 2008 for U.S. Appl. No. 11/499,520, 13 pages.
Office Action mailed on Oct. 8, 2008 for U.S. Appl. No. 11/499,529, 34 pages.
Office Action mailed on Nov. 14, 2008 for U.S. Appl. No. 11/502,875, 14 pages.
Office Action mailed on Apr. 8, 2009 for U.S. Appl. No. 11/502,876, 31 pages.
Office Action mailed on Jan. 26, 2009 for U.S. Appl. No. 11/676,124, 15 pages.
Office Action mailed on Feb. 3, 2009 for U.S. Appl. No. 10/693,059, 7 pages.
Office Action mailed on Jul. 2, 2008 for U.S. Appl. No. 10/757,803, 26 pages.
Office Action mailed on Apr. 16, 2009 for U.S. Appl. No. 12/105,010, 24 pages.
Office Action mailed on Nov. 15, 2006 for U.S. Appl. No. 10/922,034, 19 pages.
Office Action mailed on Oct. 17, 2007 for U.S. Appl. No. 10/922,034, 18 pages.
Office Action mailed on Feb. 5, 2008 for U.S. Appl. No. 10/922,034, 38 pages.
Office Action mailed on Apr. 29, 2009 for U.S. Appl. No. 12/204,572, 10 pages.

Affiliated with

Also associated with

Rating

RNA interference mediated inhibition of platelet-derived... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with RNA interference mediated inhibition of platelet-derived..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RNA interference mediated inhibition of platelet-derived... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2665393